A major grocery chain operator has agreed to pay a multimillion-dollar settlement after coming under scrutiny for pricing practices tied to one of its business segments.
The case centers not on what shoppers paid at checkout, but on allegations involving how certain prices were reported behind the scenes.
Federal officials say prescription price reporting practices caused government health care programs to pay more than they should have, resulting in a settlement worth tens of millions of dollars.
The case highlights how prescription pricing disclosures can affect taxpayer-funded health care spending, even when consumers receive discounted pharmacy prices.
Ahold Delhaize agrees to $40M settlement over prescription price data
Ahold Delhaize USA (ADRNY) has agreed to pay $40 million to resolve allegations that it submitted inflated prescription drug pricing data to federal health care programs, according to the U.S. Department of Justice (DOJ).
The company operates supermarket chains, including Giant, Hannaford, Stop & Shop, and Food Lion, many of which offer prescription savings programs that provide discounted pricing to enrolled customers.
Federal authorities alleged Ahold Delhaize did not report discounted prescription prices as its “usual and customary” rates when billing Medicare Part D, Medicaid, and Tricare. According to the government, the reporting led the programs to reimburse pharmacies at higher amounts than they otherwise would have paid.
The settlement relates to pharmacy billing practices and does not involve consumer pricing at grocery stores.
The details appear in a settlement announcement released by the Justice Department.
“Federal healthcare programs rely on pharmacies reporting accurate pricing information used in the applicable payment formulas,” Assistant Attorney General Brett Shumate of the Justice Department’s Civil Division said in a statement.
Shumate added that when pharmacies report inflated “usual and customary” prices, federal health care programs ultimately pay more than they should.
Scott J. Lampert, acting deputy inspector general for investigations at the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), said inaccurate pricing practices can undermine the integrity of taxpayer-funded health care programs.
Ahold Delhaize agrees to pay $40 million in a settlement over inflated prescription drug pricing reports.Wang Ying/Xinhua via Getty
How the Ahold Delhaize settlement will be distributed
The allegations were initially brought forward by whistleblower Lawrence LaBenne, a pharmacist who worked at an Ahold Delhaize supermarket location in Pennsylvania.
Under the civil settlement agreement, LaBenne will receive more than $6 million for reporting the alleged conduct.
Here’s some of my previous coverage on the pharmacy business:
Of the total settlement amount, approximately $32.9 million will go to the federal government, with the remaining funds distributed among participating states.
Ahold Delhaize emphasized that the settlement resolves allegations and does not include an admission of wrongdoing.
“We have admitted no wrongdoing in this matter and have fully cooperated with the government throughout the review of these government billing questions related to programs discontinued nearly a decade ago,” an Ahold Delhaize spokesperson said in an emailed statement reported by Supermarket News.
The company added that its local pharmacy brands remain committed to serving customers and supporting community health care needs.
Related: Another Mexican chain closes final restaurant, but it’s not the end
The agreement comes weeks after Ahold Delhaize released its first-quarter fiscal 2026 earnings results.
Related: Aldi follows Sam’s Club lead to win over shoppers
In that report, the company said U.S. net sales and comparable sales were negatively affected by pharmacy pricing changes tied to the Inflation Reduction Act, with a larger impact than previously predicted.
Ahold Delhaize now expects those changes to reduce U.S. pharmacy sales by approximately $450 million.
Other grocery, pharmacy chains have faced similar scrutiny
The allegations involving Ahold Delhaize reflect a broader regulatory and legal focus in the pharmacy industry, particularly regarding how discounted prescription prices are reported to federal health care programs.
Several major retailers and pharmacy operators have faced similar investigations or lawsuits tied to pricing disclosures and reimbursement practices.
CVS Health has been the subject of federal and state False Claims Act litigation over pharmacy reimbursement and billing compliance issues.
Walgreens Boots Alliance has been involved in False Claims Act litigation and settlements related to pharmacy reimbursement and prescription pricing disclosures.
While the specific allegations vary by case, they often center on how “usual and customary” prescription prices are defined and reported when pharmacies bill federal health care programs such as Medicare Part D and Medicaid.
Related: Costco tackles major frustration for members
This story was originally published by TheStreet on Jun 17, 2026, where it first appeared in the Retail section. Add TheStreet as a Preferred Source by clicking here.
Earnings Call Insights: OraSure Technologies (OSUR) Q2 2026 Management view “Q2 was another important quarter in OraSure's transformation. We exceeded...
Ooredoo Group is positioning itself to capture a multi-billion-dollar AI infrastructure opportunity by developing Indonesia’s first dedicated AI compute and...
-1024x683.jpg "The Key Battles for Senate Control Are Set")
